NMD4C Welcomes Two New Staff Members to HQ!
The NMD4C recently welcomed two staff new members to the NMD4C HQ team! Lola Owoeye, MA., joins us as the new Communications and Administrative Coordinator, and Pamela Khacho, PhD joins as the new Pre-Clinical Science Coordinator.
Lola Owoeye, MA | Communications and Administrative Coordinator
At NMD4C, she coordinates network communications, including news updates, the monthly newsletter,the website and social media platforms (Bluesky, Facebook and LinkedIn). She also manages memberships and liaises with the many people and sites involved in the network.
Pamela Khacho is our new Pre-Clinical Science Coordinator, a neuroscientist and research operations leader with a PhD and MSc in Neuroscience. Pamela has substantial experience in laboratory research, clinical trials, and regulatory affairs. She is also a Laboratory and Operations Manager at the University of Ottawa, where she supports research infrastructure and oversees lab operations.
At NMD4C, she supports the Animal and Cell-Based Research work package, including the annual summer school, the research database, the annual award competitions, and the basic science training committee.
Read next...
NMD4C Hosts 3rd Annual Basic Research Summer School at uOttawa!
From June 8 to 10, 2026, we hosted the 3rd annual NMD4C Basic Research Summer School at the University of Ottawa. The program supported 28 neuromuscular research trainees (graduate students and postdoctoral fellows) from across Canada and focused on developing practical skills, strengthening core knowledge in neuromuscular research, and providing opportunities to present and discuss their work. Through a combination of tutorials, lectures, hands-on workshops in cutting-edge wet lab techniques, flash talks, and both structured and informal networking, participants engaged with faculty, exchanged ideas, and built connections across institutions and career stages.
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.